Silexion Therapeutics Files 8-K with Corporate Updates
Ticker: SLXNW · Form: 8-K · Filed: Aug 19, 2025 · CIK: 2022416
Sentiment: neutral
Topics: corporate-governance, filing-update, name-change
Related Tickers: SLXN
TL;DR
Silexion Therapeutics (SLXN) filed an 8-K on Aug 19, 2025, detailing corporate changes and shareholder votes.
AI Summary
Silexion Therapeutics Corp. filed an 8-K on August 19, 2025, reporting on amendments to its articles of incorporation or bylaws, submission of matters to a vote of security holders, and financial statements and exhibits. The company, formerly known as Biomotion Sciences until May 6, 2024, is incorporated in the Cayman Islands and operates in the biological products sector.
Why It Matters
This filing indicates potential changes in Silexion Therapeutics' corporate structure or governance, which could impact its strategic direction and shareholder rights.
Risk Assessment
Risk Level: low — The filing is a routine corporate disclosure and does not appear to contain immediate negative financial or operational news.
Key Players & Entities
- Silexion Therapeutics Corp (company) — Registrant
- Biomotion Sciences (company) — Former company name
- August 19, 2025 (date) — Date of report
- May 6, 2024 (date) — Date of name change
- Cayman Islands (jurisdiction) — State of incorporation
FAQ
What specific amendments were made to Silexion Therapeutics' articles of incorporation or bylaws?
The filing indicates that amendments were made, but the specific details of these amendments are not provided in the summary text.
What matters were submitted to a vote of security holders?
The filing states that matters were submitted to a vote of security holders, but the nature of these matters is not detailed in the provided text.
What financial statements and exhibits are included in this 8-K filing?
The filing mentions the inclusion of financial statements and exhibits, but their specific content is not described in the provided text.
When did Silexion Therapeutics officially change its name from Biomotion Sciences?
Silexion Therapeutics Corp. officially changed its name from Biomotion Sciences on May 6, 2024.
What is Silexion Therapeutics Corp.'s Standard Industrial Classification (SIC) code and industry?
Silexion Therapeutics Corp.'s SIC code is 2836, and its industry is Biological Products (No Diagnostic Substances).
Filing Stats: 791 words · 3 min read · ~3 pages · Grade level 11.8 · Accepted 2025-08-19 10:05:34
Key Financial Figures
- $0.0135 — registered Ordinary Shares, par value $0.0135 per share SLXN The Nasdaq Stock Mar
- $1,552.50 — Ordinary Shares at an exercise price of $1,552.50 per share SLXNW The Nasdaq Stock Ma
- $20,000 — mpany's authorized share capital from US$20,000, divided into 1,481,482 ordinary shares
- $121,500 — ith a par value of US$0.0135 each, to US$121,500, divided into 9,000,000 ordinary shares
Filing Documents
- zk2533680.htm (8-K) — 54KB
- exhibit_3-1.htm (EX-3.1) — 6KB
- 0001178913-25-002985.txt ( ) — 237KB
- slxn-20250819.xsd (EX-101.SCH) — 5KB
- slxn-20250819_def.xml (EX-101.DEF) — 18KB
- slxn-20250819_lab.xml (EX-101.LAB) — 28KB
- slxn-20250819_pre.xml (EX-101.PRE) — 21KB
- zk2533680_htm.xml (XML) — 7KB
03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. At the extraordinary general meeting of Silexion Therapeutics Corp (the " Company ") originally held on August 12, 2025 and reconvened on August 19, 2025 (the " Meeting "), the shareholders of the Company duly approved a resolution serving as an effective amendment to paragraph 5 of the Company's amended and restated memorandum of association (the " Memorandum Amendment") , which increased the Company's authorized share capital, as described in Item 5.07 below. The Memorandum Amendment was filed with the Registrar of Companies of the Cayman Islands on August 19, 2025, at which time it became effective. The above description of the Memorandum Amendment is a summary of the material terms thereof and is qualified in its entirety by reference to the Memorandum Amendment, a copy of which is attached as Exhibit 3.1 hereto .
07. Submission of Matters to a Vote of Security Holders
Item 5.07. Submission of Matters to a Vote of Security Holders. On August 19, 2025, the Company reconvened the Meeting, which had been adjourned on August 12, 2025 due to the absence of a quorum. At the reconvened Meeting, holders of an aggregate of 1,459,924 ordinary shares, representing approximately 16.8% of the Company's issued and outstanding ordinary shares, were present either in person or by proxy. Pursuant to Article 21.3 of the Company's amended and restated articles of association (the " Articles "), following the lapse of a half hour from the scheduled commencement time of the reconvened Meeting, and in the absence of a quorum (defined as the presence of shareholders holding a majority of the Company's issued and outstanding ordinary shares), the shareholders then present constituted a quorum for the purpose of transacting business at the Meeting. At the reconvened Meeting, the Company's shareholders voted on the following proposal: A proposal to increase the Company's authorized share capital from US$20,000, divided into 1,481,482 ordinary shares with a par value of US$0.0135 each, to US$121,500, divided into 9,000,000 ordinary shares with a par value of US$0.0135 each. The result of the vote on this proposal was as follows: Number of Votes and % of Votes in Favor (Excluding Abstentions) Number of Votes and % of Votes Against (Excluding Abstentions) Abstentions 699,871 (59.8%) 470,828 (40.2%) 289,225 Based on the above vote result, the proposal was approved by the affirmative vote of a simple majority of the shareholders present, thereby satisfying the requisite approval threshold set forth in Article 17.1.1 of the Articles.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits 3.1 Memorandum Amendment, dated August 19, 2025 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILEXION THERAPEUTICS CORP Date: August 19, 2025 By: /s/ Ilan Hadar Name: Ilan Hadar Title: Chief Executive Officer